Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA | BSE: 524715
₹1,844.60
₹-46.70
(-2.47%)
As on 22-May-2026IST
Market cap
₹4,42,725 Cr
Revenue (TTM)
₹58,462 Cr
P/E Ratio
38.6
P/B Ratio
5.3
Div. Yield
0.9 %
Quality Score
8/10
Growth Score
7/10
Valuation Score
4/10
Momentum Score
7/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹11,479 Cr
-
ROE
16.2 %
-
ROCE
19.9 %
-
Industry P/E
31.45
-
EV/EBITDA
22.1
-
Debt to Equity
0
-
Book Value
₹348.3
-
EPS
₹51.9
-
Face value
1
-
Shares outstanding
2,399,334,970
10 Years Aggregate
CFO
₹72,747.75 Cr
EBITDA
₹94,395.47 Cr
Net Profit
₹58,337.09 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| 7.3 | 10.8 | 7.0 | 6.5 | 25.8 | 21.7 | 8.8 |
|
BSE Sensex
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
BSE Healthcare
| 8.8 | 8.8 | 9.7 | 11.0 | 27.5 | 14.1 | 12.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| -9.0 | 49.7 | 25.8 | 18.4 | 41.8 | 36.4 | -0.2 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
|
1,844.6 | 4,42,725.3 | 58,462.0 | 11,564.5 | 23.9 | 15.4 | 38.6 | 5.3 |
| 27,830.0 | 59,122.3 | 6,929.1 | 1,552.0 | 26.2 | 35.3 | 38.1 | 12.4 | |
| 1,463.5 | 84,272.7 | 33,653.1 | 3,501.5 | 14.9 | 9.7 | 24 | 2.2 | |
| 430.3 | 69,739.6 | 16,927.0 | 368.8 | 8.8 | -0.6 | 180.9 | 2.0 | |
| 1,399.2 | 1,13,007.3 | 28,162.6 | 3,869.8 | 16.6 | 12.1 | 29.1 | 3.3 | |
| 1,307.2 | 1,09,098.0 | 33,700.2 | 4,144.2 | 13.0 | 11.4 | 26 | 2.9 | |
| 2,281.8 | 1,04,222.4 | 27,958.0 | 5,355.5 | 26.6 | 27.4 | 19.5 | 4.6 | |
| 2,479.4 | 1,02,422.1 | 14,277.6 | 1,926.4 | 19.1 | 12.8 | 53.5 | 6.3 | |
| 4,486.2 | 1,51,764.0 | 13,980.0 | 2,138.0 | 24.6 | 26.5 | 70.2 | 18.1 | |
| 1,039.0 | 1,04,542.7 | 27,148.4 | 5,026.4 | 21.9 | 20.7 | 20.7 | 3.9 |
Shareholding Pattern
View DetailsNews & Analysis
All News
A hunt for quality large caps available cheap
3 min read•By Jugal Harpalani
2 min read•By Value Research
6 min read•By Kumar Shankar Roy
1 min read•By Yash Rohra
2 min read•By Mohammed Ekramul Haque
Who wins in India: Value or Growth?
3 min read•By Kumar Shankar Roy
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company... offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India. Read more
-
Incorporated
1993
-
Chairman
Dilip S Shanghvi
-
Managing Director
Kirti Ganorkar
-
Group
Sun Pharma
-
Headquarters
Vadodara, Gujarat
-
Website
Looking for more details about Sun Pharmaceutical Industries Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsAdditional Outcome Of The Board Meeting
22-May-2026No News & Announcements are available.
FAQs for Sun Pharmaceutical
What is the current share price of Sun Pharmaceutical Industries Ltd Today?
The share price of Sun Pharmaceutical Industries Ltd is ₹1,844.60 (NSE) and ₹1,845.20 (BSE) as of 22-May-2026 IST. Sun Pharmaceutical Industries Ltd has given a return of 25.83% in the last 3 years.
What is the current PB & PE ratio of Sun Pharmaceutical Industries Ltd?
The P/E ratio of Sun Pharmaceutical Industries Ltd is 38.57 times as on 22-May-2026, a 23 premium to its peers’ median range of 31.45 times.
The P/B ratio of Sun Pharmaceutical Industries Ltd is 5.30 times as on 22-May-2026, a 15 premium to its peers’ median range of 4.62 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
38.10
|
5.77
|
|
2024
|
40.60
|
6.11
|
|
2023
|
27.84
|
4.21
|
|
2022
|
67.07
|
4.57
|
|
2021
|
49.38
|
3.09
|
What is the 52 Week High and Low of Sun Pharmaceutical Industries Ltd?
The 52-week high and low of Sun Pharmaceutical Industries Ltd are Rs 1,916.60 and Rs 1,548.00 as of 23-May-2026.
What is the market cap of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a market capitalisation of ₹ 4,42,725 Cr as on 22-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Sun Pharmaceutical Industries Ltd?
Before investing in Sun Pharmaceutical Industries Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.